Drug Patents owned by Onyx Therap

1. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8207125 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(2 years from now)

US7232818 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(2 years from now)

US8207297 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(2 years from now)

US7417042 ONYX THERAP Compounds for enzyme inhibition
Jul, 2026

(3 years from now)

CN102174076A ONYX THERAP Compounds For Enzyme Inhibition
Nov, 2014

(7 years ago)

CN100526221C ONYX THERAP Chromium Salt Water Solution And Its Manufacturing Method
Nov, 2024

(2 years from now)

CN1886342A ONYX THERAP Chromium Salt Water Solution And Its Manufacturing Method
Nov, 2024

(2 years from now)

CN101044157B ONYX THERAP Compound For Proteasome Inhibition
Apr, 2025

(2 years from now)

CN101006098B ONYX THERAP Compound For Inhibiting Proteasome Enzyme
Apr, 2025

(2 years from now)

CN101044157A ONYX THERAP Compound For Inhabiting Proteasome
Apr, 2025

(2 years from now)

CN102286070B ONYX THERAP Compound For Proteasome Inhibition
Apr, 2025

(2 years from now)

CN102286070A ONYX THERAP Compound For Proteasome Inhibition
Apr, 2025

(2 years from now)

CN101006098A ONYX THERAP Compound For Inhibiting Proteasome Enzyme
Apr, 2025

(2 years from now)

IN200605644P1 ONYX THERAP Compounds For Enzyme Inhibition
Apr, 2025

(2 years from now)

IN255964B ONYX THERAP Compounds For Enzyme Inhibition
Apr, 2025

(2 years from now)

EP1745064A2 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Apr, 2025

(2 years from now)

EP1745064B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Apr, 2025

(2 years from now)

EP2270026B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2270026A2 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2266999A2 ONYX THERAP Compounds For Proteasome Enzym Inhibition
Aug, 2025

(2 years from now)

EP2266999B1 ONYX THERAP Compounds For Proteasome Enzym Inhibition
Aug, 2025

(2 years from now)

EP3101026A1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2266999A3 ONYX THERAP Compounds For Proteasome Enzym Inhibition
Aug, 2025

(2 years from now)

EP3101026B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2270026A3 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP1781688A1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP1781688B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7491704 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US8207127 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US8207126 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US8129346 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US7737112 ONYX THERAP Composition for enzyme inhibition Dec, 2027

(5 years from now)

US9511109 ONYX THERAP Combination therapy with peptide epoxyketones Oct, 2029

(7 years from now)

US9493582 ONYX THERAP Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.